Exaggerated inflammatory response after use of recombinant bone morphogenetic protein in recurrent unicameral bone cysts

Journal of Pediatric Orthopaedics

Volumn 30, Issue 2, 2010, Pages 199-205

  MacDonald, Kevin M ^a   Swanstrom, Morgan M ^a   McCarthy, James J ^a   Nemeth, Blaise A ^a   Guliani, Teresa A ^a   Noonan, Kenneth J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BONE BIOPSY; BONE CYST; BONE MATRIX; BONE RADIOGRAPHY; CASE REPORT; CHILD; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; INTRAMEDULLARY NAILING; LIMB PAIN; LIMB SWELLING; MALE; MEDICAL RECORD REVIEW; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; SCHOOL CHILD; SOLITARY BONE CYST; TREATMENT FAILURE;

BONE CYSTS; BONE MORPHOGENETIC PROTEINS; CHILD; FEMALE; HUMANS; INFLAMMATION; MALE; RECOMBINANT PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR BETA; TREATMENT FAILURE;

EID: 77649158924     PISSN: 02716798     EISSN: None     Source Type: Journal    
DOI: 10.1097/BPO.0b013e3181cec35b     Document Type: Article

References (48)

1. Lokiec F, Ezra E, Khermosh O, et al. Simple bone cysts treated by percutaneous autologous marrow grafting. A preliminary report. J Bone Joint Surg Br. 1996;78:934-937.
2. Lokiec F, Wientroub S. Simple bone cyst: etiology, classification, pathology, and treatment modalities. J Pediatr Orthop B. 1998;7: 262-273.
3. Schreuder HW, Conrad EU III, Bruckner JD, et al. Treatment of simple bone cysts in children with curettage and cryosurgery. J Pediatr Orthop. 1997;17:814-820.
4. Stanton RP, Abdel-Mota'al MM. Growth arrest resulting from unicameral bone cyst. J Pediatr Orthop. 1998;18:198-201.
5. Neer CS, Francis KC, Johnston AD, et al. Current concepts on the treatment of solitary unicameral bone cyst. Clin Orthop Related Res. 1973;97:40-51.
6. Scaglietti O, Marchetti PGM, Bartolozzi P. The effects of methylprednisolone acetate in the treatment of bone cysts. J Bone Joint Surg. 1979;61:200-204.
7. Scaglietti O, Marchetti PGM, Bartolozzi P. Final results obtained in the treatment of bone cysts with methylprednisolone acetate (Depo-Medrol) and a discussion of results achieved in other bone lesions. Clin Orthop Related Res. 1982;165:33-42.
8. Oppenheim WL, Galleno H. Operative treatment versus steroid injection in the management of unicameral bone cysts. J Pediatr Orthop. 1984;4:1-7.
9. Goel AR, Kriger J, Bronfman R, et al. Unicameral bone cysts: treatment with methylprednisone acetate injections. J Foot Ankle Surg. 1994;33:6-15.
10. Wright JG, Yandow S, Donaldson S, et al. A randomized clinical trial comparing intralesional bone marrow and steroid injections for simple bone cysts. J Bone Joint Surg Am. 2008;90:722-730.
11. Wilkins RM, Kelly CM, Giusti DE. Bioassayed demineralized bone matrix and calcium sulfate: use in bone-grafting procedures. Ann Chir Gynaecol. 1999;88:180-185.
12. Wilkins RM. Unicameral bone cysts. J Am Acad Orthop Surg. 2000; 8:217-224.
13. Killian JT, Wilkinson L, White S, et al. Treatment of unicameral bone cyst with demineralized bone matrix. J Pediatr Orthop. 1998; 18:621-624.
14. Neer CS II, Francis KC, Marcove RC, et al. Treatment of unicameral bone cyst: a follow-up study of one hundred seventy-five cases. J Bone Joint Surg Am. 1966;48:731-745.
15. Spence KF Jr, Bright RW, Fitzgerald SP, et al. Solitary unicameral bone cysts: treatment with freeze-dried crushed cortical-bone allograft: a review of one hundred and forty-four cases. J Bone Joint Surg Am. 1976;58:636-641.
16. Spence KF, Sell KW, Brown RH. Solitary bone cyst: treatment with freeze-dried cancellous bone allograft: a study of one hundred seventy-seven cases. J Bone Joint Surg Am. 1969;51:87-96.
17. Farber JM, Stanton RP. Treatment options in unicameral bone cysts. Orthopedics. 1990;13:25-32.
18. Sung AD, Anderson ME, Zurakowski D, et al. Unicameral bone cyst: a retrospective study of three surgical treatments. Clin Orthop Relat Res. 2008;466:2519-2526.
19. Cook SD, Salkeld SL, Brinker MR, et al. Use of an osteoinductive biomaterial (rhOP-1) in healing large segmental bone defects. J Orthop Trauma. 1998;12:407-412.
20. Kirker-Head CA, Gerhart TN, Armstrong R, et al. Healing bone using recombinant human bone morphogenetic protein 2 and copolymer. Clin Orthop Relat Res. 1998;349:205-217.
21. Sciadini MF, Johnson KD. Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. J Orthop Res. 2000;18:289-302.
22. Burkus JK, Gornet MF, Dickman CA, et al. Anterior lumbar interbody fusion using rhBMp-2 with tapered interbody cages. J Spinal Disord Tech. 2002;15:337-349.
23. Csimma C, Govender S, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am. 2002;84:2123-2134.
24. Urist MR. Bone: formation by autoinduction. Science. 1965;150: 893-899.
25. Zlotolow DA, Vaccaro AR, Salamon ML, et al. The role of human bone morphogenetic proteins in spinal fusion. J Am Acad Orthop Surg. 2000;8:3-9.
26. Martin GJ, Boden SD, Titus L. Recombinant human bone morphogenetic protein-2 overcomes the inhibitory effect of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), on postero- lateral lumbar intertransverse process spine fusion. Spine. 1999; 24:2188-2194.
27. Haid RW, Branch CL, Alexander JT, et al. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J. 2004;4: 527-539.
28. Mummaneni PV, Pan J, Haid RW, et al. Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. J Neurosurg Spine. 2004;1:19-23.
29. Slosar PJ, Josey R, Reynolds J. Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes. Spine J. 2007;7: 301-307.
30. Oluigbo CO, Solanki GA. Use of recombinant human bone morphogenetic protein-2 to enhance posterior cervical spine fusion at 2 years of age: technical note. Pediatr Neurosurg. 2008;44: 393-396.
31. Richards BS, Welch RD, Shrader MW, et al. Use of rhBMP-2 in congenital pseudoarthrosis of the tibia. Presented at the Annual Meeting of the Pediatric Orthopedic Society of North America, Ottawa, Ontario. May 12-15, 2005.
32. Vander Have KL, Hensinger RN, Caird M, et al. Congenital pseudarthrosis of the tibia. J Am Acad Orthop Surg. 2008;16: 228-236.
33. Smucker JD, Rhee JM, Singh K, et al. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine. 2006;31:2813-2819.
34. Shields LB, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine. 2006;31: 542-547.
35. Tumialan LM, Rodts GE. Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion. Spine J. 2007;7:509-510.
36. Perri B, Cooper M, Lauryssen C, et al. Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case study. Spine J. 2007;7:235-239.
37. McClellan JW, Mulconrey DS, Forbes RJ, et al. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech. 2006;19: 483-486.
38. Joseph V, Rampersaud YR. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine. 2007;32:2885-2890.
39. Wong DA, Kumar A, Jatana S, et al. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off- label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J. 2008;8:1011-1018.
40. Sanfilippo JA, Lee JY, Rihn J, et al. BMP-2 causes increased postoperative radiculitis following TLIF. Presented at the 2007 Annual Meeting of the North American Spine Society.
41. Sanfilippo JA, Lee JY, Rihn J, et al. Increased post-operative radiculitis when BMP-2 is used with transforaminal interbody fusion. Presented at the 2008 Annual Meeting of the American Academy of Orthopedic Surgeons.
42. Marusic A, Grcevic D, Katavic V, et al. Role of B lymphocytes in new bone formation. Lab Invest. 2000;80:1761-1774.
43. Marusic A, Katavic V, Grcevic D, et al. Genetic variability of new bone induction in mice. Bone. 1999;25:25-32.
44. Hsu WK, Lieberman JR. The role of bone graft substitutes in total hip arthroplasty. In: Callaghan JJ, Rosenberg AG, Rubash HE, eds. The Adult Hip. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:329-334.
45. Sheehan JP, Kallmes DF, Sheehan JM, et al. Molecular methods of enhancing lumbar spine fusion. Neurosurgery. 1996;39:548-554.
46. Fischgrund JS, James SB, Chabot MC, et al. Augmentation of autograft using rhBMP-2 and different carrier media in the canine spinal fusion model. J Spinal Disord. 1997;10:467-472.
47. Kirker-Head CA. Potential applications and delivery strategies for bone morphogenetic proteins. Adv Drug Deliv. 2000;43:65-92.
48. Burg KL, Porter S, Kellam JF. Biomaterial developments for bone tissue engineering. Biomaterials. 2000;21:2347-2359.